Nystatin and Triamcinolone Acetonide Ointment Recall Due to cGMP Deviations
Teligent Pharma is recalling all unexpired batches of Nystatin and Triamcinolone Acetonide Ointment (15g, 30g, and 60g tubes) nationwide due to current Good Manufacturing Practice (cGMP) deviations related to discontinuation of the stability study program.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall with no reported illnesses or injuries. The hazard is a manufacturing-practice deviation (discontinuation of stability studies) that creates theoretical risk but is not associated with documented patient harm. The precautionary nature and lack of reported adverse events place this in the Moderate category.
Plain-English summary
Teligent Pharma, Inc. is recalling Nystatin and Triamcinolone Acetonide Ointment, USP in three package sizes: 15-gram tubes (NDC 52565-042-15), 30-gram tubes (NDC 52565-042-30), and 60-gram tubes (NDC 52565-042-60). The recall affects approximately 217,184 tubes distributed nationwide in the USA and Puerto Rico.
The recall is being issued because the firm is discontinuing its stability study program, which constitutes a deviation from current Good Manufacturing Practice (cGMP) standards. All products within their expiration dates are included in the recall.
Patients taking this medication should consult their healthcare provider or pharmacist before stopping use. Consumers with affected product should contact their pharmacy or healthcare provider for guidance on obtaining replacement medication or alternative treatment options.
The recalled product
- Product
- Nystatin and Triamcinolone Acetonide Ointment, USP, packaged in a) 15 grams tubes, NDC 52565-042-15; b) 30 grams tubes, NDC 52565-042-30; c) 60 grams tubes, NDC 52565-042-60, Rx Only, Manufactured by: Teligent Pharma, Inc., Buena, NJ 08310.
- Manufacturer
- Teligent Pharma, Inc.
- Category
- Drug — Topical Ointment
- Hazard
- cgmp-deviation
- stability-study-discontinuation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Batch: a) 15125
- Exp. 2/28/2022
- 15385
- Exp. 3/31/2022
- 15613
- Exp. 5/31/2022
- 16027
- Exp. 9/30/2022
- 16204
- Exp. 11/30/2022
- 16376
- Exp. 1/31/2023
- 16707
- Exp. 3/31/2023
- b) 15385
- 15752
- Exp. 6/30/2022
- 15346
- 16188
- 16567
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-06-17
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27